Search bioRxiv⌕ Search

Biology subjects

Contessotto, P.

Publications and source records attributed to Contessotto, P..

2 recordsLinked to original sources

Microtubule architecture connects AMOT stability to YAP/TAZmechanotransduction and Hippo signaling

Cellular mechanotransduction is a fundamental informational system by which cells read the structural features of their environment to control their own form and function. The YAP/TAZ transcriptional regulators are universal effectors of physical signals. Yet, the identity of proteins and subcellular structures serving as mechano-rheostats remains elusive. Here we demonstrate that perinuclear centrosome and microtubules architecture act functionally downstream of F-actin as cornerstones of cellular mechanotransduction. The mechanism revolves around the stability of AMOT proteins, that act as cytoplasmic inhibitory sinks for YAP/TAZ. Being degraded in mechano-activated cells and stabilized in mechanically-inhibited cells, AMOT serves as primary mechanical rheostat. In mechanically inhibited cells, microtubules form a cage-like network surrounding the nucleus, but, in mechanically activated cells, switch their architecture with formation of the centrosome from which microtubules sprout toward the cell periphery. In these conditions, AMOT proteins bound to the Dynein/Dynactin complex are subject to fast retrograde transport through the microtubular aster toward the pericentrosomal proteasome for quantitative and timely degradation. Restoring centrosomal condensation in mechanically inhibited cells by NLP1 overexpression is sufficient to restore mechanosignaling and YAP activation. AMOT proteins serves as universal integrator of distinct physical inputs from the ECM and the cytoskeleton, and their ablation renders cells invariably mechano-insensitive. Our findings also provide a unifying model that mechanistically merges mechanosignaling with the Hippo cascade. The current model by which YAP/TAZ are regulated by Hippo kinases is through direct YAP/TAZ phosphorylation. Our data instead show that, at least in the context of mechanotransduction, Hippo signaling inhibits YAP/TAZ largely indirectly, through LATS phosphorylation of AMOT averting it from its degradation route. We further show that Ras/RTK oncogenes hijack the AMOT degradation route to promote YAP/TAZ-mediated tumorigenesis. The findings imply the AMOT stabilization machinery as novel target for YAP/TAZ therapeutic modulation. In sum, our work reveals a previously unknown hierarchical coordination of distinct cytoskeletal and transport systems orchestrating mechanosignaling at the whole cell level.

cell biology↗

Reproducing extracellular matrix adverse remodelling of non-ST myocardialinfarction in a large animal model

The rising incidence of non-ST-segment elevation myocardial infarction (NSTEMI) and associated long-term high mortality constitutes an urgent clinical issue. Unfortunately, the study of possible interventions to treat this pathology lacks a reproducible pre-clinical model. Indeed, currently adopted small and large animal models of MI mimic only full-thickness, ST-segment-elevation (STEMI) infarcts, and hence cater only for investigation into therapeutics and interventions directed at this subset of MI. Thus, we developed an ovine model of NSTEMI by ligating the myocardial muscle at precise intervals parallel to the left anterior descending coronary artery. After validating the presented model both by histology and functional analysis with clinical data, further omics analyses highlighted the distinctive features of post-NSTEMI tissue remodelling. Here, by looking at the transcriptome and proteome-derived pathways emerging at acute (7 days) and late (28 days) post-surgery timepoints, we discovered specific alterations in cardiac post-ischaemic extracellular matrix (ECM). Together with the rise of well-known markers of inflammation and fibrosis, NSTEMI ischaemic regions showed distinctive patterns in the expression of complex N-glycans and glycosaminoglycans in cellular membranes and ECM. Identifying such changes in molecular moieties accessible to infusible and intra-myocardial injectable drugs sheds light on the development of targeted pharmacological solutions to contrast adverse fibrotic remodelling.

bioengineering↗